) and vancomycin-resistant E. faecalis (MICs ≥4 µg mL -1
Traditional medications for the treatment of CDI (vancomycin and metronidazole) are inadequate as reinfection occurs in 15−35% of patients. 3, 4 Fidaxomicin was approved by the Food and Drug Administration in 2011 for the treatment of CDI, exhibiting a decrease in recurrence relative to that of vancomycin and metronidazole. 6, 7 Potential CDI chemotherapeutics are currently under various stages of development, these include REP3123, 8 nitazoxanide, 9 fusidic acid, 5 teicoplanin, 5, 10 LFF571, 11 CB-183 315 12 and cationic nylon-3 polymers. 13 Furthermore, monoclonal antitoxin antibodies are under investigation as potential treatments for CDI recurrence. 7 This intense interest in novel CDI therapeutics is a direct result of the inadequacy of current medications, the continuing cost to the healthcare sector and the emergence of hypervirulent strains.
Previous research in our laboratory has led to the development of a promising new class of antimicrobials based upon a binaphthyl-tripeptide structure (e.g., 1, Fig. 1 ).
14−16
These derivatives exhibit selective inhibition of Gram negative bacteria, as well as broad-spectrum activity against
Gram positive bacteria including vancomycin-, linezolid-and methicillin-resistant strains.
14 −16 Efficacy has been translated in vivo, both topically and systemically, for infections of the latter. 14 A rudimentary pharmacophore has emerged comprising an anchoring (semi)rigid aromatic core (binaphthyl/biphenyl), two cationic residues and a hydrophobic moiety at the peptide Cterminus.
With a continuing interest in expanding the applications of these binaphthyl-based antimicrobials, we were inspired to investigate their potential as chemotherapeutics for CDI. We envisioned that the non-drug-like features and high molecular weight of these molecules would ensure limited oral bioavailability, making them ideal candidates for the treatment of gastrointestinal infections. Initial inspiration came from preliminary in vitro testing of 1 against C. difficile, which exhibited a promising minimum inhibitory concentration (MIC) of 8 µg mL -1 against two problematic ribotype 027 strains. This is the first example of this class of compounds inhibiting an anaerobic bacterial strain. Therefore, this lead compound formed the basis of this current study, which aimed to replace the terminal ester with a peptidomimetic 1,2,3-triazole moiety 17 for increased metabolic stability in the gut. 
Results and Discussion
The synthetic binaphthyl-1,2,3-triazole peptides for this investigation were divided into three target classes (A−C) based on the number of embedded amino acid residues (Fig. 2) . Class A was the starting point for our molecular design, given that is an isostere analogue of our existing broad-spectrum antibacterials which incorporate three amino acid residues (e.g., ester 1). Smaller peptide classes B and C, bearing two and one amino acid residues respectively, were chosen as additional targets to establish the necessary components for activity against C. difficile and other bacterial pathogens. Within classes A and C, we also planned to perform minor variations in the amino acid identity at AA Our previous studies have shown that all stereoisomers of 1 have similar activity, 14 thus we aimed to incorporate the unnatural D-configured cationic residues due to an expected increase in enzymatic stability. An overview of our proposed synthetic strategy is shown in Scheme 1, exemplified with a Class B scaffold. The peptide backbone would be assembled from the N-terminus by the iterative coupling of protected amino acid and amino azide components, resulting in a net-replacement of the C-terminus with an azide moiety. This modular approach would allow variation of the number and type of amino acid residues incorporated, enabling straightforward access to all three target classes. The terminal triazole ester isostere, common to all target peptides, could then be assembled by cycloadditions with alkynes and arynes. Finally, basic amino functionalities would be revealed as their hydrochloride salts by acidolysis of the Boc and 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) protecting groups. 
22−26
The synthesis of Class A compounds began with the coupling of lysine-based acid 2 14 and protected arginine ester 3, 27 giving dipeptide 4 in 92% yield after saponification (Scheme 2a).
This intermediate was coupled with leucine-derived amino azide 5 28 and separately, the novel arginine-derived amino azide 14 (Scheme 2b) to give terminal azides 6 and 15, respectively, in near quantitative yields. Excess amine (1.5−2.0 equiv) was necessary during these reactions to avoid competitive consumption of 4 via intramolecular attack of its protected guanidine on the activated acid, which occurred as a side reaction under stoichiometric conditions. With azide 6 in hand, copper-catalyzed click reactions (conditions A, Fig. 3 ) with selected terminal alkynes proceeded smoothly to produce triazoles 7−9 in 63−93% yields (Scheme 2a).
The hydrophobic nature of the binaphthyl-azide constituted the need for a 4:1 t-BuOH:H 2 O binary solvent, as opposed to the standard 1:2 t-BuOH:H 2 O more polar medium. 22 The quantities of inexpensive reagents: alkyne, Cu(OAc) 2 and Na·ascorbate were not optimized due to the small scale of the reactions (<0.1 mmol of azide). Prior to deprotection of the leucine-containing Class A compounds, alcohol 7 was converted to its methyl ether derivative 10. Subsequent treatment of 8−10 with TFA, followed by anion exchange with ethereal HCl, afforded dihydrochloride salts 11−13 (Scheme 2a; insert). Similarly, a tricationic Class A derivative 17 was prepared in good overall yield via cycloaddition of 15 with 5-methyl-1-hexyne (Scheme 2b). Scheme 3 Synthesis of Class B triazoles bearing two amino acid residues. See Table 1 Silylacetylenes reacted slowly under the copper catalyzed conditions and afforded mixtures containing de-silylated products. Therefore, thermal Huisgen cycloaddition was used for these substrates, allowing the sterically controlled installation of trimethylsilyl (TMS) and dimethylphenylsilyl groups at R 2 in high yields (conditions C, entries 9 and 10). Fused benzotriazole 42 was synthesized via the cycloaddition of azide 18 with in situ generated benzyne (conditions E, Table 1 , entry 24). 26 This protocol was also extended to a heteroaryne, producing the indole-fused triazole 43 in a reasonable 58% yield, albeit as an approximate 2:1 mixture of regioisomers (entry 25). The structure of the major isomer could not be determined due to poor resolution of regioisomeric peaks in the 1 H NMR spectrum, however it is noteworthy that a previous indolyltriazole formed in this manner showed moderate preference for azide attack (triazole N-1) at the indole 5-position (2.4:1 isomeric ratio). 30 Commercially available pyridyne precursors were also screened in this (hetero)aryne cycloaddition, however, with the need to utilize azide 18 as the limiting reagent, pyridine polymerization 31 occurred almost exclusively over the desired cycloaddition. Although the preferred regiochemical outcome of conditions A−D could be confidently inferred from literature precedent, 22−25 we were able to confirm the expected orientations of representative triazoles 28, 30, 31 and 41 by two-dimensional HSQC and HMBC NMR experiments (Fig. 4) . In each case, a through-bond correlation between the methylene hydrogens adjacent to the triazole and C-5 of the ring provided unequivocal evidence of the assigned structure. With the exception of triazole ester 38, all Class B triazoles documented in Table 1 Finally, Class B ester 38 was used for the synthesis of amide derivatives after saponification to carboxylic acid 84 (Scheme 6). Initially, we were surprised to find that neither our standard EDCI·HCl/HOBt coupling conditions nor a HATU/(i-Pr) 2 NEt system were successful for amide bond formation, resulting in recovery of unreacted starting materials. Eventually, we found that acid 84 could be activated as a mixed anhydride, 32 although excess reagents were necessary to obtain synthetically useful yields of the desired amides. After establishing an extensive set of Class B triazoles, we turned our attention to the synthesis of monocationic Class C compounds; details are given in Scheme 7. The required lysine and arginine-based azides 91 and 98 were readily obtained by the coupling of acid 89 14 with amino azides 90 33 and 14, respectively. Each azide was then subjected to copper catalyzed cycloadditions with a small set of previously employed hydrophobic alkynes (Table 2) . Interestingly, cycloadditions of lysine-derived azide 91 with benzyl and isopentyl-substituted alkynes were rather slow; heating to 35 °C for 46−48 h was required for complete azide consumption ( Table 2, entries 2 and 3), in contrast to the arginine analogue 98, which reacted completely at rt within 24
h. This reactivity difference revealed a theretofore hidden accelerating effect of the remote guanidine moiety, presumably by coordination to the copper catalyst.
Scheme 7
Synthesis of Class C triazoles bearing one amino acid residue. See Table 2 for specific click conditions and yields. In vitro bacterial testing results for the three triazole classes A−C are presented in Tables 3−5, respectively. Lead compound 1 was included as a positive control throughout, in addition to vancomycin and chloramphenicol for Gram positive and Gram negative strains, respectively.
Three C. difficile human isolates were evaluated including 027 ribotypes from Canada (M7404) and the UK (R20291). 34 Our initial results with Class A tripeptides 11−13 were encouraging (Table 3, aureus, E. faecalis and S. pneumoniae strains (Table 4, (Table 4) . Aryl, alkyl and silylbased groups were all conducive to good activity, while the incorporation of polar functional groups such as an alcohol ( A related dependence on hydrophobic termini also emerged from the testing of Class B compounds against Gram negative E. coli (Table 4) . Triazole substituents such as isopentyl, cyclohexyl, TMS and benzyl provided optimal MICs of 4 µg mL -1 (entries 4, 5, 7, 11 and 17), representing a four-fold increase in potency relative to that of compound 1.
Class C compounds with a single amino acid residue were also active against C. difficile, with
MICs ranging from 4−16 µg mL -1 (Table 5 , entries 2−9). Strong bacterial inhibition was also maintained for Gram positive S. aureus and E. faecalis strains. Class C triazoles derived from arginine were generally more active than their lysine-based analogues; for instance, comparison of phenyl-substituted triazoles 95 and 104 derived from lysine and arginine, respectively, showed at least a two-fold increase in potency for the latter for six out of the eight strains tested (Table 5, entry 2 versus entry 5). Notably, Class C triazoles were completely inactive against E. coli, establishing the need for two basic side chains for Gram negative activity.
Selected Class B compounds bearing hydrophobic termini were also tested against additional bacterial isolates ( Although the precise antimicrobial mechanism of our binaphthyl-peptides has not yet been fully elucidated, the observation that all three compound classes A−C were active suggests a general mode of action. Related cationic peptides have been shown to operate via a membrane depolarization mechanism.
35
Resistance studies with C. difficile are in progress within our laboratories to identify a potential binding target for our newly developed molecules. 
Conclusions
In conclusion, we have prepared forty six triazole ester isostere analogues of the antibacterial dicationic tripetide 1, with the aim of developing metabolically more stable molecules suitable for targeting C. difficile infections in the gut. These analogues were synthesized employing Cu-or ((R)-6-(((R)-1-(4-hexyl-1H-1,2,3-triazol-1-yl)-5-(2-((2,2,4,6,7-pentamethyl-2,3- 
tert-Butyl

dihydrobenzofuran-5-yl)sulfonyl)guanidino)pentan-2-yl)amino)-5-(2-(((S)-2'-(isopentyloxy)-
[1,1'-binaphthalen]-2-yl)oxy)acetamido)-6-oxohexyl)carbamate (22) . This compound was prepared according to general procedure 2 using azide 18 (50.0 mg, 0.047 mmol), Cu(OAc) 2 ·H 2 O (1.9 mg, 0.0094 mmol), Na·ascorbate (3.7 mg, 0.019 mmol), 1-octyne (15.6 mg, 0.14 mmol), tBuOH (1.0 mL) and H 2 O (0.25 mL) with a 24 h reaction time. Work-up as described gave 22 (52.0 mg, 94%) as an off-white solid. TLC (100% EtOAc) R F = 0.10; 
